Dr. Karin received his BSc in Biology from Tel Aviv University in 1975 and his Ph.D. in Molecular Biology from the University of California Los Angeles in 1979. He is currently a Distinguished Professor of Pharmacology and Pathology at the University of California San Diego School of Medicine, where he has been on the faculty since 1986.
Dr. Karin has received numerous awards for his outstanding research. He was a cofounder of Signal Pharmaceutical, which has become a part of Celgene, Inc. Dr. Karin’s current activity primarily focuses on understanding the relationship between inflammation, cancer, and metabolic disease as well as the signaling mechanisms used by receptors involved in inflammation and innate immunity.
In addition to discovering some of the most important stress- and inflammation-responsive signal transduction pathways and establishing molecular links between obesity, inflammation and cancer, Dr. Karin’s work has revealed new targets for cancer prevention and therapy as well as for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases.